The partners are advancing a comprehensive report on how the detected PGx markers impact drug response and customized reports focusing on specific types of drugs.
Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers.
Under the deal, Novacyt's Primerdesign business will work with Applied Microarrays on the development of microarray-based diagnostic assays.
The assay will combine the company's CytoSort assay with its automated AIR system for imaging, sorting, and isolating single cells and small colonies.
Although the two studies seem to provide conflicting results on the impact of PGS, the "devil's in the details," according to an outside expert.
The company's total revenues were $23.1 million, supported by growth across the firm's instrument and consumables sales, and its research collaboration business.
The test is designed to identify a tumor's tissue of origin by assessing 2,000 individual genes and covers 15 common tumor types.
The exclusive two-way licensing deal also allows Akonni to commercialize Righton's molecular diagnostic tests outside of China.
The company aims to shore up its core nCounter platform business with new consumables, as it continues to work on new technologies and explore clinical translation.
The company's total revenues were $35.2 million during the quarter compared to $25.2 million during the same period in 2016. Full-year results also beat analyst estimates.
The $649 NGS test screens for 193 disorders, can be ordered online, and is designed to supplement standard state newborn screening services.
A jury agreed that Ariosa's noninvasive prenatal test infringed several claims in two patents held by Illumina.
The two companies are entering a partnership to introduce diagnostic tests using NanoString's nCounter technology in Japan, beginning with a lymphoma assay.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
The firm sold more than 4.9 million shares of common stock at $15 per share, raising $73.7 million to expand its commercial operations and grow its technology.
The firm plans to use the proceeds to expands its commercial operations, expand its existing technology, and support the launch of its new platform.
Clearbridge subsidiary SAM Laboratory will be the exclusive provider of NanoString's Prosigna breast cancer prognostic gene signature assay in certain countries.
Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.
Veracyte attributed its lower Afirma sales in part to slowing down the rollout of an updated version of the test that relies on RNA sequencing.
The shelf registration follows a recent $56.5 million financing and comes amid an expansion of the firm's commercial operations.